ES2113865T3 - Gen pnc humano y proteina precursora. - Google Patents

Gen pnc humano y proteina precursora.

Info

Publication number
ES2113865T3
ES2113865T3 ES91116557T ES91116557T ES2113865T3 ES 2113865 T3 ES2113865 T3 ES 2113865T3 ES 91116557 T ES91116557 T ES 91116557T ES 91116557 T ES91116557 T ES 91116557T ES 2113865 T3 ES2113865 T3 ES 2113865T3
Authority
ES
Spain
Prior art keywords
human
pnc
gen
precursor protein
cnp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91116557T
Other languages
English (en)
Inventor
Shoji Tanaka
Kayoko Fuchimura
Yasunori Tawaragi
Hisayuki Matsuo
Kenji Kangawa
Naoto Minamino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Application granted granted Critical
Publication of ES2113865T3 publication Critical patent/ES2113865T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EL GEN DE UN CNP HUMANO (PEPTIDO NATRIURETICO DE TIPO C HUMANO), ASI COMO LA PROTEINA PRECURSORA DE HCNP QUE ESTA CODIFICADA POR ESTE GEN. EL PRECURSOR DE HCNP ESTA REPRESENTADO POR LA SIGUIENTE SECUENCIA DE AMINOACIDO. EL PRECURSOR DE HCNP Y SUS DERIVADOS SON NUEVOS Y TIENEN ACTIVIDADES NATRIURETICAS E HIPOTENSORAS.
ES91116557T 1990-09-27 1991-09-27 Gen pnc humano y proteina precursora. Expired - Lifetime ES2113865T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP02259698A JP3026354B2 (ja) 1990-09-27 1990-09-27 ヒトｃｎｐ遺伝子及び前駆体蛋白

Publications (1)

Publication Number Publication Date
ES2113865T3 true ES2113865T3 (es) 1998-05-16

Family

ID=17337688

Family Applications (2)

Application Number Title Priority Date Filing Date
ES91116557T Expired - Lifetime ES2113865T3 (es) 1990-09-27 1991-09-27 Gen pnc humano y proteina precursora.
ES96114549T Expired - Lifetime ES2302333T3 (es) 1990-09-27 1991-09-27 Gen de un cnp humano y proteina precursora.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES96114549T Expired - Lifetime ES2302333T3 (es) 1990-09-27 1991-09-27 Gen de un cnp humano y proteina precursora.

Country Status (8)

Country Link
US (1) US6034231A (es)
EP (2) EP0769554B1 (es)
JP (1) JP3026354B2 (es)
AT (2) ATE388165T1 (es)
DE (2) DE69133593T2 (es)
DK (1) DK0477971T3 (es)
ES (2) ES2113865T3 (es)
GR (1) GR3026554T3 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
BR0316560A (pt) 2002-11-26 2005-10-04 Nobex Corp Conjugado de composto natriurético, formulação farmacêutica, método de tratar uma condição, método de preparação do conjugado de composto natriurético, conjugado de peptìdeo pró-polinatriurético modificado, análogo de peptìdeo natriurético, análogo de hbnp, composto, e, método de preparar um composto
EP3620530A1 (en) 2004-03-31 2020-03-11 Kazuwa Nakao Composition for increasing body height
WO2005094889A1 (ja) 2004-03-31 2005-10-13 Chugai Seiyaku Kabushiki Kaisha 関節炎症治療剤又は予防剤
PL2348114T3 (pl) 2004-04-21 2019-08-30 Alexion Pharmaceuticals, Inc. Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
US20070184466A1 (en) * 2005-11-18 2007-08-09 The Brigham And Women's Hospital, Inc. Detection, generation and uses of atherosclerosis-protective endothelium
EP2217620A2 (en) * 2007-11-21 2010-08-18 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
KR20130018965A (ko) * 2008-05-23 2013-02-25 다이이찌 산쿄 가부시키가이샤 목적 펩타이드의 혈장내 반감기 연장 작용을 가진 펩타이드
HUE032582T2 (en) 2009-05-20 2017-09-28 Biomarin Pharm Inc Variants of c-type natriuretic peptide
EP2658979B1 (en) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
WO2016090251A1 (en) 2014-12-05 2016-06-09 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
CA2994280C (en) 2015-07-30 2024-01-23 Biomarin Pharmaceutical Inc. Use of c-type natriuretic peptide variants to treat skeletal dysplasia
AU2016308624B2 (en) 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
CA3008017C (en) 2016-01-08 2024-01-02 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN
KR20180125979A (ko) 2016-04-01 2018-11-26 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
MX2019011508A (es) 2017-03-31 2019-11-01 Alexion Pharma Inc Metodos para tratar la hipofosfatasia (hpp) en adultos y adolescentes.
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
JP7820148B2 (ja) 2018-08-10 2026-02-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法
WO2021055497A1 (en) 2019-09-16 2021-03-25 Biomarin Pharmaceutical Inc. Cnp variants and conjugates thereof
MX2022007114A (es) 2019-12-09 2022-07-11 Alexion Pharma Inc Polipeptidos de fosfatasa alcalina y metodos de uso de los mismos.
MX2023002673A (es) 2020-09-04 2023-05-12 Alexion Pharma Inc Métodos para el tratamiento de trastornos de mineralización ósea.
EP4291224A4 (en) 2021-02-12 2025-01-01 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
WO2023283657A1 (en) 2021-07-09 2023-01-12 Biomarin Pharmaceutical Inc. C-type natriuretic peptide variants to treat skeletal dysplasia in children
CN119013035A (zh) 2021-12-07 2024-11-22 生物马林药物股份有限公司 骨相关病症的c型利钠肽疗法
US12077561B2 (en) 2022-11-02 2024-09-03 Novo Nordisk A/S CNP compounds
AU2024283779A1 (en) 2023-06-07 2026-01-22 Biomarin Pharmaceutical Inc. High throughput screen for genetic variants associated with short stature
WO2025101863A1 (en) 2023-11-08 2025-05-15 Biomarin Pharmaceutical Inc. Cnp variants, conjugates and formulations thereof
WO2026030743A1 (en) 2024-08-02 2026-02-05 Biomarin Pharmaceutical Inc. Treatment of short stature with cnp variants

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339210C (en) * 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
EP0769554A3 (en) 1997-05-28
EP0477971A3 (en) 1992-09-09
US6034231A (en) 2000-03-07
EP0477971A2 (en) 1992-04-01
ATE388165T1 (de) 2008-03-15
DE69133593T2 (de) 2009-04-02
JP3026354B2 (ja) 2000-03-27
ATE162532T1 (de) 1998-02-15
EP0769554A2 (en) 1997-04-23
DE69128754T2 (de) 1998-06-04
JPH04139199A (ja) 1992-05-13
DK0477971T3 (da) 1998-09-21
EP0477971B1 (en) 1998-01-21
GR3026554T3 (en) 1998-07-31
DE69133593D1 (de) 2008-04-17
DE69128754D1 (de) 1998-02-26
EP0769554B1 (en) 2008-03-05
ES2302333T3 (es) 2008-07-01

Similar Documents

Publication Publication Date Title
ATE162532T1 (de) Merschliches cnp-gen und vorläufer protein
DK499485A (da) Peptid
IL131016A0 (en) Selection of proteins using rna-protein fusions
ATE125269T1 (de) Radiomarkierte peptide mit antikoagulanswirkung.
ATE104348T1 (de) O-glycosyliertes ifn-alpha.
ATE110743T1 (de) Antikoagulierende peptide.
DE3789413D1 (de) Lymphokin-ähnliche Peptide.
ES2184728T3 (es) Proteinas de union a la fibronectina.
ES548617A0 (es) Procedimiento para disociar peptidos y proteinas en el enla-ce metionilo
KR950702242A (ko) 사포린 함유 단백질의 재조합 생산방법(Recombinant production of saporin-containing proteins)
ATE107859T1 (de) Verwendung von antiprogestomimetika zur stimulierung des eisprungs.
HU906270D0 (en) Anticoagulant peptides
ITRM920658A0 (it) Procedimento per la purificazione della proteina endotelina
ZA899247B (en) Anticoagulant peptides
DK0477217T3 (da) Stabiliserede, potente GRF-analoge
FI944997A0 (fi) Parannettu rekombinantti-proteiinien tuotanto
DE3869939D1 (de) Biologisch wirksame peptide.
DE59610098D1 (de) Protein mit anti-tumorwirkung
ITRM920517A1 (it) Procedimento di produzione della proteina sv-iv ricombinante e proteina sv-iv ricombinante.
DK136088D0 (da) Peptid
ATE75255T1 (de) Peptid und dafuer kodierendes gen.
DK369888A (da) Peptidforbindelser
ATE103339T1 (de) Lymphokin-aehnliche peptide.
ATE95238T1 (de) Leader-anteile zur produktion von rekombinanten proteinen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 477971

Country of ref document: ES